Investigating novel pharmacological pathways to potentially bypass SSRI-induced sexual dysfunction via alternate histaminergic-dopaminergic routes.
The exploratory research published in Sexual Medicine (Regis & Pfaus, 2026) identifies a potential mechanism of central excitation. Qualitative case studies suggest that diphenhydramine hydrochloride may act as a facilitator of sexual response in specific metabolic profiles, offering preliminary observational evidence of an alternative pathway around SSRI-induced suppression.
Enhanced genital sensitivity, intensified orgasmic sensations, and psychological catharsis reported among surveyed individuals experiencing paradoxical excitation.
A notable case study (Subject F4) reported a perceived override of antidepressant-induced sexual inhibition, maintaining arousal and orgasmic capacity during DPH ingestion.
The paper proposes that ultrarapid metabolism of DPH by the CYP2D6 enzyme in specific profiles may convert the compound into an active agent with stimulant or disinhibitory properties.
Exploring central nervous system routes that may operate independently of standard serotonergic suppression to mediate sexual excitation.
SSRIs increase synaptic serotonin, which can downstream inhibit central arousal. Standard H1-antagonism additionally causes peripheral dryness and sedation.
We hypothesize that ultrarapid CYP2D6 metabolizers convert the compound to an active metabolite, triggering paradoxical excitation instead of sedation.
Investigating alternate dopaminergic and histaminergic pathways that may disinhibit the central arousal system to restore sensory response.
Paradoxica is opening our Pre-Seed funding round to secure foundational intellectual property, protect pathway hypotheses, and prepare protocols for formal clinical studies.
Scientific partners and early venture investors may request the Paradoxica Pre-Seed deck and initial clinical hypothesis outline by authenticating below.